Table 2.

Summary of the in vivo chemopreventive, anticancer, and antimetastatic effects of RSV against OSCC-related animal models: tested concentrations, times, and general results.

In Vivo Dose and Timing	Animal Models	Results	Reference
2 mg of RSV, 2 mg of CUR, or 4 mg of an RSV+CUR combination per os two weeks before or simultaneously with SALTO treatment	BALB/c treated with SALTO cancer cell line	The 33% of the cases treated by the combination of RSV+CUR displayed complete cancer regression, synergic effects, and safety.	Masuelli et al. [42]
Intraperitoneal administration of RSV 100 mg/kg daily alone or in combination with cetuximab (10 mg/kg three times weekly)	Xenografted nude BALB/cAnNCrj-nu/nu mice	Suppression of tumor growth and downregulation of uPAR expression. Synergic effect with cetuximab due to overcoming the drug resistance phenomenon.	Uzawa et al. [44]
Buccal administration of 74.5 mM of RSV (ethanol solution) or cream and mouthwash containing the RSV–HPCD complex two times a week	Syrian golden hamsters treated with neoplastic agent	Chemopreventive effects leading to a reduction in OPLs. The RSV–HPCD complex mouthwash highlighted the best efficacy.	Berta et al. [53]